Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial

The Lancet

Volumn 371, Issue 9627, 2008, Pages 1854-1860

  Janssens, Hein JEM ^a   Janssen, Matthijs ^b   van de Lisdonk, Eloy H ^a   van Riel, Piet LCM ^a   van Weel, Chris ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NAPROXEN; PLACEBO; PREDNISOLONE; URATE;

ABDOMINAL PAIN; ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DYSPNEA; ESOPHAGUS PAIN; FATIGUE; FEMALE; FOLLOW UP; FOOT EDEMA; GOUT; HEADACHE; HEART PALPITATION; HICCUP; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; SWEATING; TREMBLING EYELID; VISUAL ANALOG SCALE; WEIGHT GAIN;

EID: 44349087738     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60799-0     Document Type: Article

References (37)

1. Terkeltaub R. Gout. N Engl J Med 349 (2003) 1647-1655
2. Porter R., and Rousseau G. Gout, the patrician malady (2000), Yale University Press, New Haven, London
3. Ordi J., Alonso P., de Zulueta J., et al. The severe gout of Holy Roman Emperor Charles V. N Engl J Med 355 (2006) 516-520
4. Zhang W., Doherty M., Bardin T., et al. EULAR evidence based recommendations for gout, part I: diagnosis-report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65 (2006) 1301-1311
5. Choi H., Atkinson K., Karlson E., Willett W., and Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363 (2004) 1277-1281
6. Janssens H., van de Lisdonk E., Janssen M., van den Hoogen H., and Verbeek A. Gout, not induced by diuretics? A case-control study from primary care. Ann Rheum Dis 65 (2006) 1080-1083
7. Choi H., and Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: a prospective cohort study. BMJ 336 (2008) 309-312
8. Bieber J., and Terkeltaub R. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 50 (2004) 2400-2414
9. Brook R., Kleinman N., Patel P., et al. The economic burden of gout on an employed population. Curr Med Res Opin 22 (2006) 1381-1389
10. Ahern M., Reid C., Gordon T., McCredie M., Brooks P., and Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 17 (1987) 301-304
11. Schlesinger N., Schumacher H., Catton M., and Maxwell L. Colchicine for acute gout. Cochrane Database Syst Rev 4 (2006) CD006190.
12. Petersel D., and Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol 34 (2007) 1566-1568
13. Underwood M. Diagnosis and management of gout. BMJ 332 (2006) 1315-1319
14. Sutaria S., Katbamna R., and Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout-a systematic review. Rheumatology 45 (2006) 1422-1431
15. Rostom A., Muir K., Dubé C., et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 5 (2007) 818-828
16. Lewis S., Langman M., Laporte J., Matthews J., Rawlins M., and Wiholm B. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 54 (2002) 320-326
17. Kearney P., Baigent C., Godwin J., Halls H., Emberson J., and Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
18. Laporte J., Ibanez L., Vidal X., Vendrell L., and Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 27 (2004) 411-420
19. Antman E., Bennett J., Daugherty A., Furberg C., Roberts H., and Taubert K. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115 (2007) 1634-1642
20. Lawrence R., Felson D., and Helmick C. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States, part II. Arthritis Rheum 58 (2008) 26-35
21. Fam A. Gout in the elderly: clinical presentation and treatment. Drugs Aging 13 (1998) 229-243
22. Janssens H., van de Lisdonk E., Bor H., van den Hoogen H., and Janssen M. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract 20 (2003) 413-416
23. Krishnan E., Baker J., Furst D., and Schumacher H. Gout and the risk of acute myocardial infarction. Arthritis Rheum 54 (2006) 2688-2696
24. Rowe B., Spooner C., Ducharme F., Bretzlaff J., and Bota G. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 1 (2001) CD002178.
25. Gotzsche P., and Johansen H. Short-term low-dose corticosteroids vs placebo and nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev 1 (2005) CD000189.
26. Janssens H., Lucassen P., Van de Laar F., Janssen M., and Van de Lisdonk E. Systemic steroids for acute gout. Cochrane Database Syst Rev 2 (2008) CD005521.
27. Alloway J., Moriarty M., Hoogland Y., and Nashel D. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 20 (1993) 111-113
28. Siegel L., Alloway J., and Nashel D. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 21 (1994) 1325-1327
29. Man C., Cheung I., Cameron P., and Rainer T. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 49 (2007) 670-677
30. Todd K., Funk K., Funk J., and Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med 27 (1996) 485-489
31. Stahmer S., Shofer F., Marino A., Shepherd S., and Abbuhl S. Do quantitative changes in pain intensity correlate with pain relief and satisfaction?. Acad Emerg Med 5 (1998) 5851-5857
32. ten Klooster P., Drossaers-Bakker K., Taal E., and van de Laar M. Patient-perceived satisfactory improvement (PPSI): interpreting meaningful change in pain from the patient's perspective. Pain 121 (2006) 151-157
33. Groff G., Franck W., and Raddatz D. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 9 (1990) 329-336
34. Werlen D., Gabay C., and Vischer T. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum Engl Ed 63 (1996) 248-254
35. Schumacher Jr. H., Edwards L.-R., Becker M., et al. Outcome measures for acute and chronic gout. J Rheumatol 32 (2005) 2452-2455
36. Schlesinger N., Detry M., Holland B., et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 29 (2002) 331-334
37. Lanza F., and Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 93 (1998) 2037-2046